Afrezza Affinity 1

Shares of MannKind (NASDAQ: MNKD) are down approximately 2 percent amid comments from Summer Street analyst Bart Classen. Classen reported in an interview that MannKind's briefing documents may be “problematic” regarding Affinity 1 studies on the Afrezza Dreamboat insulin inhaler. The analyst...